References
- Nissen-Meyer R., Kjellgren K., Malmio K., et al. Surgical adjuvant chemotherapy: Results with one short course with cyclophosphate after mastectomy for breast cancer. Cancer 1978; 41: 2088–98
- Nissen-Meyer R., Høist H., Kjellgren K., et al. One short chemotherapy course given immediately after mastectomy: experience of the SACSG. INSERM 1986; 137: 157–64
- Nissen-Meyer R., Høst H., Kjellgren K., . Neoadjuvant chemotherapy in breast cancer—as single perioperative treatment and with supplementary long-term Chemotherapy. Adjuvant therapy of cancer, S. E Salmon, et al. Grune and Stratton Inc, Orlando 1987; 253–61
- Nolvadex Adjuvant Trial Organisation Controlled trial of tamoxifen as an adjuvant agent in management of early breast cancer. Lancet 1983; 1: 257–62
- Nolvadex Adjuvant Trial Organisation Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1985; 1: 836–40
- Wilson A. J, Baum M, Brinkley D. M, et al. Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. World J Surg 1985; 9: 75644
- CRC Adjuvant Breast Trial Working Party. Cyclophosph-amide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988, in press
- Houghton J., Baum M., Nissen-Meyer R., et al. Is there a role for perioperative adjuvant therapy in the treatment of early breast cancer. Eur J Surg Oncol 1987, in press
- Anonymous Review of mortality results in randomized trials in early breast cancer. Lancet 1984; 2: 1205
- Dnistrian A. M, Mortonk K., Schwartz M. K, et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and post menopausal breast cancer patients. Cancer 1983; 51: 803–7
- Padmanabhan N., Howell A., Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986; 2: 4114
- Rose D. P, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977; 1: 1174–6
- Palshof T. Adjuvant endocrine therapy in the management of primary breast cancer. Rev Endo-Rel Cancer 1981; 7: 65–75, suppl
- Pritchard K. I, Meakin J. W, Boyd N. F, . A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. 4th Int Conf on the Adjuvant Therapy of Cancer, S. E Jones, S. E Salmon, et al. Tucson 1984; 33W7, Abstr 49
- Ribeiro G., Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: Report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 1983; 286: 827–30
- Rose C., Thorpe S. M, Mouridsen H. T, et al. Anti-oestrogen Treatment of postmenopausal women with high risk breast cancer. Breast Cancer Res Treat 1983; 3: 77–84
- Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; 2: 1714
- Wallgren A., Glas U., Theve N. C, . Adjuvant tamoxifen in operable breast cancer in Stockholm. Proc of 13th International Congress of Chemotherapy, K. H Spitzy, K. Karrer, et al. Vienna 1983; 18: 15–7
- National Institutes of Health, Consensus development. Conference statement: Adjuvant chemotherapy for breast cancer 1985; 5(12)
- BCTCS/UICC/WHO. Breast Cancer Trials Review Meeting, Washington. September, 1985